Evidence map›Paper›PMID 30326852›Full record

ArticleBMC cancer2018

A rare case of primary breast angiosarcoma in a male: a case report.

Benedito Borges da Silva, Walberto Monteiro Neiva Eulálio Filho, Pedro Vitor Lopes Costa, Rozirene Araújo Silva, Ariton Mendes Conde Junior, Diego Cipriano Chagas, Mariella de Almeida Melo, Fidelis Manes Neto, Cleciton Braga Tavares, Edilson Carvalho de Sousa Júnior and 4 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Benedito Borges da SilvaPostgraduate Program of the Northeast Network of Biotechnology (RENORBIO), Federal University of Piauí, Teresina, Brazil. beneditoborges@globo.com.ORCID http://orcid.org/0000-0002-9542-7538
Walberto Monteiro Neiva Eulálio FilhoGetúlio Vargas Hospital, Federal University of Piauí, Elias Joao Tajra Avenue, 1260, CEP, Teresina, Piauí, 64049-300, Brazil.
Pedro Vitor Lopes CostaPostgraduate Program in Health Sciences, Federal University of Piaui, Teresina, Brazil.
Rozirene Araújo SilvaGetúlio Vargas Hospital, Federal University of Piauí, Elias Joao Tajra Avenue, 1260, CEP, Teresina, Piauí, 64049-300, Brazil.
Ariton Mendes Conde JuniorPostgraduate Program in Health Sciences, Federal University of Piaui, Teresina, Brazil.
Diego Cipriano ChagasPostgraduate Program in Health Sciences, Federal University of Piaui, Teresina, Brazil.
Mariella de Almeida MeloPostgraduate Program in Health Sciences, Federal University of Piaui, Teresina, Brazil.
Fidelis Manes NetoPostgraduate Program in Health Sciences, Federal University of Piaui, Teresina, Brazil.
Cleciton Braga TavaresPostgraduate Program of the Northeast Network of Biotechnology (RENORBIO), Federal University of Piauí, Teresina, Brazil.
Edilson Carvalho de Sousa JúniorPostgraduate Program of the Northeast Network of Biotechnology (RENORBIO), Federal University of Piauí, Teresina, Brazil.
Eid Gonçalves CoelhoGetúlio Vargas Hospital, Federal University of Piauí, Elias Joao Tajra Avenue, 1260, CEP, Teresina, Piauí, 64049-300, Brazil.
Viriato CampeloPostgraduate Program in Health Sciences, Federal University of Piaui, Teresina, Brazil.
Luis Henrique GebrimPostgraduate Program of the Northeast Network of Biotechnology (RENORBIO), Federal University of Piauí, Teresina, Brazil.
Raimundo Gerônimo da Silva JuniorPostgraduate Program in Health Sciences, Federal University of Piaui, Teresina, Brazil.
Universidade Federal do Piauí · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSarcomas account for less than 1% of primary breast cancers, and breast angiosarcomas are responsible for only 0.05% of all breast malignancies. The male breast has the same potential for malignant transformation as the female breast. However, due to anatomical differences in the breast and the low incidence of angiosarcoma, it is difficult to determine how male breasts can be affected by this type of tumor. CASE PRESENTATION: A 36-year-old male patient was admitted to the hospital with a palpable lump in his right breast. Lymphadenopathy was negative. Ultrasonography showed a hypoechoic mass with partially defined contours, measuring 4.0 × 3.0 cm, with muscle infiltration. Histological examination revealed a malignant tumor. Radical mastectomy was then performed with clear surgical margins. The patient began chemotherapy with paclitaxel. Following the second cycle of chemotherapy, he presented with headache and seizures due to a frontal lobe metastasis. Twenty days after the onset of neurological symptoms, the patient died.

conclusionsPrimary angiosarcomas of the male breast are extremely rare. This is the sixth case published in the literature. It is in agreement with other studies in the literature concerning clinical presentation and poor prognosis. Treatment consists in surgical removal of the tumor with clear margins and without axillary lymphadenectomy.

Indexed as

Breast Neoplasms, MaleHemangiosarcomaAdultBrain NeoplasmsChemotherapy, AdjuvantHumansMalePaclitaxelPaclitaxelAngiosarcomaBreastMale

Identifiers

PMID30326852
PMCPMC6192278
OpenAlexW2897702014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.